LAUSR

MIN score predicts primary response to infliximab/adalimumab and vedolizumab therapy in patients with inflammatory bowel diseases.

Sign Up to like & get
recommendations!
1 Published in 2021 at "Genomics"

DOI: 10.1016/j.ygeno.2021.04.011

Abstract: Infliximab/adalimumab (IFX/ADA) and vedolizumab (VDZ) are the most widely used biologics in inflammatory bowel diseases. Current models used to predict their efficacies are restricted to either Crohn's disease or ulcerative colitis or to only one… read more here.

Keywords: ifx ada; vdz; inflammatory bowel; bowel diseases ... See more keywords